RecruitingPhase 4NCT05455359

Gastrointestinal Dysmotility on Aspiration Risk

The Impact of Upper Gastrointestinal Dysmotility on Aspiration-associated Symptoms

Sponsor

Boston Children's Hospital

Enrollment

120 participants

Start Date

Feb 13, 2025

Study Type

INTERVENTIONAL

Conditions

aspiration pneumonia Gastro Esophageal Reflux Esophageal Motility Disorders Gastric Motor Dysfunction

Summary

The hypothesis of this study is that esophageal and gastric dysmotility increase the risk of developing aspiration-associated symptoms in children with neurologic impairment. The investigators are conducting a ten week cross over study comparing prucalopride to famotidine for the treatment of aspiration-associated symptoms.

Eligibility

Min Age: 5 YearsMax Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Famotidine and a drug called Prucalopride for people with esophageal motility disorders, gastric motor dysfunction, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 5 Years to 21 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.